Bill Text: TX HB551 | 2023-2024 | 88th Legislature | Introduced
Bill Title: Relating to a study on the prevalence of the use of psychoactive or psychotropic medication by persons who have committed suicide.
Spectrum: Partisan Bill (Republican 1-0)
Status: (Introduced - Dead) 2023-02-23 - Referred to Public Health [HB551 Detail]
Download: Texas-2023-HB551-Introduced.html
| By: Toth | H.B. No. 551 | |
|
|
||
|
|
||
| relating to a study on the prevalence of the use of psychoactive or | ||
| psychotropic medication by persons who have committed suicide. | ||
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
| SECTION 1. (a) In this Act: | ||
| (1) "Commission" means the Health and Human Services | ||
| Commission. | ||
| (2) "Psychoactive medication" has the meaning | ||
| assigned by Section 242.505, Health and Safety Code. | ||
| (3) "Psychotropic medication" has the meaning | ||
| assigned by Section 266.001, Family Code. | ||
| (b) The commission shall conduct a study evaluating the | ||
| prevalence of the use of psychoactive or psychotropic medication by | ||
| persons who are reported to have committed suicide. The study must | ||
| evaluate: | ||
| (1) for persons for whom a report described by | ||
| Subsection (c) indicated the use of psychoactive or psychotropic | ||
| medication: | ||
| (A) the period of time the person was taking | ||
| psychoactive or psychotropic medication; | ||
| (B) the medication the person was taking; | ||
| (C) whether there is evidence of the person | ||
| experiencing withdrawal symptoms; and | ||
| (D) if applicable, the period of time the person | ||
| was experiencing withdrawal symptoms; and | ||
| (2) for persons for whom a report described by | ||
| Subsection (c) did not indicate the use of psychoactive or | ||
| psychotropic medication: | ||
| (A) whether there is evidence of the person | ||
| having recently discontinued using psychoactive or psychotropic | ||
| medication; and | ||
| (B) whether there is evidence of the person | ||
| experiencing withdrawal symptoms. | ||
| (c) In conducting the study, the commission shall use | ||
| autopsy reports, toxicology reports, police reports, and other | ||
| information related to persons who are reported to have committed | ||
| suicide that are: | ||
| (1) collected between January 1, 2016, to December 31, | ||
| 2022; and | ||
| (2) concerning persons who resided in counties with a | ||
| population of 450,000 or more. | ||
| (d) Not later than October 1, 2023, the commission shall | ||
| prepare and submit to the governor, the lieutenant governor, and | ||
| the speaker of the house of representatives a written report | ||
| containing the results of the study. | ||
| (e) The study required by this Act is a public record under | ||
| Chapter 552, Government Code. | ||
| (f) The commission shall comply with all applicable state | ||
| and federal laws regarding personally identifiable information in | ||
| conducting the study. | ||
| SECTION 2. This Act takes effect September 1, 2023. | ||
